MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,812K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Accounts payable
Proceeds from issuance of at-the...
Others
Negative Cash Flow Breakdown
Change in fair value of warrants
Accrued expenses and other liabi...
Prepaid expenses and other curre...
Change in fair value of continge...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-1,155
-11,793
-37,137
-4,538
Depreciation
20
19
20
19
Stock-based compensation expense
1,659
1,932
1,592
414
Non-cash issuance of common stock
-
-
250
-
Loss on issuance of warrants
-
-
0
0
Loss on extinguishment of debt
0
-76
-
-
Change in fair value of convertible notes
-213
-8,727
-17,549
-1,877
Change in fair value of warrants
-4,941
-4,656
1,016
237
Loss on derivative liability
0
1,743
13,088
-
Change in fair value of contingent consideration
-11
-4
10
-37
Prepaid expenses and other current assets
179
-10
-1,092
-338
Accounts payable
1,216
539
-1,583
-1,382
Accrued expenses and other liabilities
-541
700
331
481
Other assets and liabilities
-21
-71
940
5
Net cash used in operating activities
-3,698
-2,636
-4,712
-2,596
Purchases of property and equipment
-
-
0
0
Net cash used in investing activities
-
-
0
0
Proceeds from issuance of shares, net-At Market Offering
-
-
0
168
Proceeds from issuance of public offering shares, net-Public Offering
-
-
18,346
-
Proceeds from pipe financing
0
4,208
-
-
Proceeds from issuance of shares, net-Public Offering
-
-
-
18,346
Proceeds from issuance of shares, net-Private Placement
-
-
1,791
-
Proceeds from issuance of at-the-market shares, net
886
1,665
-
-
Net cash provided by financing activities
886
5,873
1,791
84
Net increase in cash
-2,812
3,237
-2,921
-2,512
Cash and cash equivalents at beginning of period
6,243
3,006
5,927
13
Cash and cash equivalents at end of period
3,431
6,243
3,006
5,927
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
at-the-market shares, net
$886K
(954.76%↑ Y/Y)
Net cash provided by
financing activities
$886K
(-95.19%↓ Y/Y)
Net increase in cash
-$2,812K
(-133.37%↓ Y/Y)
Canceled cashflow
$886K
Stock-based compensation
expense
$1,659K
(-49.89%↓ Y/Y)
Accounts payable
$1,216K
(160.71%↑ Y/Y)
Change in fair value of
convertible notes
-$213K
(93.89%↑ Y/Y)
Other assets and
liabilities
-$21K
(-400.00%↓ Y/Y)
Depreciation
$20K
(-48.72%↓ Y/Y)
Net cash used in
operating activities
-$3,698K
(63.02%↑ Y/Y)
Canceled cashflow
$3,129K
Change in fair value of
warrants
-$4,941K
(94.27%↑ Y/Y)
Net (loss) income
-$1,155K
(-147.09%↓ Y/Y)
Accrued expenses and
other liabilities
-$541K
(82.07%↑ Y/Y)
Prepaid expenses and
other current assets
$179K
(-26.94%↓ Y/Y)
Change in fair value of
contingent consideration
-$11K
(99.68%↑ Y/Y)
Buy us a coffee
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)